Pages that link to "Q38762808"
Jump to navigation
Jump to search
The following pages link to Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. (Q38762808):
Displaying 35 items.
- The effect of SGLT2 inhibitors on cardiovascular events and renal function. (Q38614488) (← links)
- Effects of conjugated linoleic acid supplementation on serum C-reactive protein: A Systematic Review and meta-analysis of Randomized Controlled Trials. (Q38677443) (← links)
- Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. (Q47293312) (← links)
- Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects (Q47739163) (← links)
- Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study (Q47871089) (← links)
- SGLT2 Inhibitors and Mechanisms of Hypertension (Q49937324) (← links)
- Are SGLT2 Inhibitors Ready for Prime Time for CKD? (Q50146720) (← links)
- The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus (Q51731100) (← links)
- Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. (Q55053753) (← links)
- Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials. (Q55380047) (← links)
- Effect of magnesium supplements on serum C-reactive protein: a systematic review and meta-analysis. (Q55652249) (← links)
- Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention: JACC Health Promotion Series (Q57025355) (← links)
- Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention (Q57936185) (← links)
- Use of dapagliflozin in patients with advanced diabetic kidney disease (Q58795412) (← links)
- The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition (Q59335403) (← links)
- Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis (Q61806030) (← links)
- Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials (Q64063460) (← links)
- Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors (Q89506074) (← links)
- Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis (Q90726814) (← links)
- Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a sup (Q91723697) (← links)
- Dietary choline is positively related to overall and cause-specific mortality: results from individuals of the National Health and Nutrition Examination Survey and pooling prospective data (Q91750976) (← links)
- New Therapeutic Strategies for Type 2 Diabetes CME (Q91780179) (← links)
- Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017 (Q92092668) (← links)
- Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis (Q92095965) (← links)
- TRPV1 Antagonists as Novel Anti-Diabetic Agents: Regulation of Oral Glucose Tolerance and Insulin Secretion Through Reduction of Low-Grade Inflammation? (Q92178204) (← links)
- Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus (Q92369466) (← links)
- Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide (Q92510342) (← links)
- SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects (Q92703271) (← links)
- Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes (Q92835456) (← links)
- The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit (Q92916727) (← links)
- SGLT2 inhibition to address the unmet needs in diabetic nephropathy (Q93173024) (← links)
- Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases (Q93184566) (← links)
- Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review (Q96955195) (← links)
- SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients (Q98612863) (← links)
- Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus (Q98778627) (← links)